Replies to post #168439 on Enzolytics Inc (ENZC)

[Valuator2]

You could be right, but it depends on structure of the deal and what the pharmaceutical plant produces, neither of which has been revealed yet. BTW, neither has the legal structure of the "Licensing Entity"...corporation, partnership, etc....which has an impact on how and when ENZC reports the results of that operation on its own books. Per the Footnote:

The Licensing Entity is the owner of a pharmaceutical plant in Eastern Europe. Pursuant to the Agreement, Enzolytics will receive $1 Million USD and 50% ownership in the Licensing Entity valued at $8 Million.

Since the "Licensing Entity" (the parent) owns the pharmaceutical plant, and ENZC owns 50% of the parent entity, ENZC should share in 50% of the profit/loss of the pharmaceutical plant that flows up to the parent entity. IPF manufacturing costs would be included if that plant is used for its production, so associated IPF revenues would have to come into play at some point along the line of reporting unless IPF is excluded by some mechanism within the agreement.

My question is where and when will the 50% of the $8 million value of the Licensing Entity be recorded on ENZC's fins...as an asset and revenues. It appears to me to be a part of the sales price of the license, together with the $1 million, and should be recorded as an asset to be accounted for on the equity basis (as opposed to a subsidiary). Maybe there's a contingency or something left to be negotiated.

[BonnieMac]

I was referring to the 2 products that are very similar but not the same: "Enzolytics IPF Immune", which is Enzolytics' product, which Enzolytics owns 100%, & "Enzoimmune", which is Rosetta Lifecare Bulgaria's product-- which Enzolytics has some sort of 50% stake or ownership in-- the exact details of which have not been divulged.
This has nothing to do with the ITV-1 patent or product which I understand is to treat HV-Aids.

[Timing101]

Foxi and all
-
Pg 4 and Pg 14
https://www.otcmarkets.com/otcapi/company/financial-report/351987/content
--
a. you are correct in you DD posting in the language
b. Valentin D , CEO and Chairman of Rosetta Lifecare , holds ENZC (new and improved) Series E Preferred Shares . Pg 4 above. He and his group are 'neworked' with ENZC . It is quite possible the last company will be (or continue to advance with them) lised on Pg 14.
More to come. (distribution and so forth as stated)
c. There is no company left off my posting , it is directly from the most recent disclosure.
--
on ward and forward, Lets get that SEC Format done for filing !

[Capt_Smith77]

This helps clear up a lot of the confusion I had, and makes sense.

The company already has a minimum of 27 interested retailers for distribution in North America for IPF, both in retail as well as online distribution. The plan is to then expand into Europe, as well as Latin America, and it looks like this other company has rights to Asia and Africa, though non-exclusive. IIRC, I believe some licensing agreements for "ROW" require a minimum sales order before royalties kick in. Even if that isn't the case, you're waiting on ITV-1 ROW sales, which should be a gold mine for both companies, IMO.